Menu Close

With PD-1 OK looming, Regeneron antes $100M on bluebird alliance for next-gen TCR cell therapy pact

For Regeneron and bluebird, it’s a chance to considerably widen the horizon of cell therapy targets — adding a variety of intracellular TCR targets. And bluebird fattens a cash reserve that was recently built up with a whopping $632 million raise … (본문 전체 8/6/2018 9:32 PM)